Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Adjuvant Chemotherapy in NPC with Post-radiation EBV DNA
NCT02363400Phase 3Terminated
- Sponsor
- National Health Research Institutes
- Start
- Dec 2014
- Primary completion
- Dec 2021
- Modality
- DNA Intercalators/Alkylators
- Countries
- 1
01
Overview
A Phase 3 trial of mitomycin c, epirubicin, cisplatin, tegafur + uracil in nasopharyngeal carcinoma (NPC), sponsored by National Health Research Institutes. Started Dec 2014; status: terminated.
02
Drugs
mitomycin cepirubicincisplatintegafur + uracil
03
Conditions
nasopharyngeal carcinoma (NPC)
Beyond the preview
Go deeper on NCT02363400.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02363400.